Biofil Chemicals & Pharmaceuticals

BIOFILCHEM · NSE

— · —

₹31.52

Closing price — 29 Sept 2026

Market cap ₹51 Cr · EPS ₹0.76

Valuation

Blended fair value using DCF and peer comparison methods.

See if Biofil Chemicals & Pharmaceuticals is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

Cyclical company. DCF based on normalised positive cash flows only. Peer comparison weighted more heavily.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Biofil Chemicals & Pharmaceuticals BIOFILCHEM · you	₹51 Cr	18.4×	2.4×	78.6×	12.9%	9.8%	-1.9%
Sector median	—	25.8×	2.0×	8.0×	6.9%	1.4%	0.6%
Hemant Surgical Industries Limited HSIL	₹531 Cr	29.1×	—	—	—	—	—
Fabtech Technologies Limited FABTECH	₹478 Cr	14.7×	1.6×	8.0×	9.1%	9.3%	28.5%
Jenburkt Pharmaceuticals Ltd. JENBURPH	₹469 Cr	14.3×	3.0×	—	20.8%	0.2%	—
Albert David Limited ALBERTDAVD	₹462 Cr	—	1.2×	—	-0.4%	-0.4%	-0.8%
Prevest Denpro Limited PREVEST	₹458 Cr	21.4×	—	—	—	—	—
Valiant Laboratories Limited VALIANTLAB	₹451 Cr	34.2×	2.0×	—	5.8%	0.1%	—
HALEOS LABS LIMITED HALEOSLABS	₹449 Cr	25.8×	2.1×	11.1×	8.1%	5.2%	1.9%
Bajaj Healthcare Limited BAJAJHCARE	₹444 Cr	49.3×	2.1×	6.3×	3.0%	2.6%	-1.8%

Peer comparison verdict

Biofil looks attractively valued — trading at a discount to sector peers on P/E (18.4× vs sector median 25.8×) while delivering above-average returns on equity (12.9% vs 6.9%).

Business quality

Valuation

P/E ratio

18.4×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

12.9%

ROCE

1.7%

ROA

—

Growth

Revenue CAGR (3yr)

-1.9%

EPS CAGR (3yr)

70.8%

Efficiency

Asset turnover

—

FCF yield

-1.6%

Dividend yield

—

Liquidity & Solvency

Debt / Equity

0.14×

Debt / EBITDA

—

Interest coverage

38.0×

Current ratio

1.73×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹28 Cr

Net profit

₹3 Cr

Operating margin

—

Net margin

9.8%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

-₹0.6 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

-₹0.8 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹3 Cr

Equity

₹22 Cr

Debt / Equity

0.14×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

46.8%

FII

0.0%

DII

0.1%

Retail

53.1%

Trend over time (%)

Quarterly data

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Change (YoY)
Promoter	46.8%	46.8%	46.8%	46.8%	46.8%	46.8%	46.8%	46.8%	46.8%	46.8%	46.8%	46.8%	-0.0 ppYoY
FII (Foreign)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0 ppYoY
DII (Domestic)	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0 ppYoY
Retail	53.1%	53.1%	53.1%	53.1%	53.1%	53.1%	53.1%	53.1%	53.1%	53.1%	53.1%	53.1%	+0.0 ppYoY

Signals from the trend

➡️

PromoterStable — no notable buying or selling

➡️

FIIStable

➡️

DIIStable

Shareholding pattern has been broadly stable — no strong signals in either direction.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.